Showing posts with label Build. Show all posts
Showing posts with label Build. Show all posts
ScienceDaily (Oct. 27, 2011) — Researchers have built a map that shows how thousands of proteins in a fruit fly cell communicate with each other. This is the largest and most detailed protein interaction map of a multicellular organism, demonstrating how approximately 5,000, or one third, of the proteins cooperate to keep life going.

"My group has been working for decades, trying to unravel the precise connections among the proteins and gain insight into how the cell functions as a whole," says Spyros Artavanis-Tsakonas, Harvard Medical School professor of cell biology and senior author on the paper. "For me, and hopefully researchers studying protein interactions, this map is a dream come true."

The study is published October 28 in the journal Cell.

While genes are a cell's data repository, containing all the instructions necessary for life, proteins are its labor force, talking to each other constantly and channeling vital information through vast and complicated networks to keep life stable and healthy. Humans and fruit flies are both descended from a common ancestor, and in most cases, both species still rely on the same ancient cellular machinery for survival. In that respect, the fruit fly's map serves as sort of a blueprint, a useful guide into the cellular activity of many higher organisms.

Understanding how proteins behave normally is often the key to their disease-causing behavior.

For this study, Artavanis-Tsakonas and his colleagues provide the first large-scale map of this population of proteins. Their map, which is not yet fully complete, reveals many of the relationships these myriad proteins make with each other as they collaborate, something which, to date, has been to a large degree an enduring mystery among biologists.

"We already know what approximately one-third of these proteins do," Artavanis-Tsakonas said. "For another third of them we can sort of guess. But there's another third that we know nothing about. And now through this kind of analysis we can begin to explore the functions of these proteins. This is giving us extraordinary insight into how the cell works."

One significant use for such a map is to assess how a cell responds to changes in metabolic conditions, such as interactions with drugs or in conditions where genetic alterations occur. Finding such answers might lead to future drug treatments for disease, and perhaps to a deeper understanding of what occurs in conditions such as cancer.

"This is of extraordinary translational value," Artavanis-Tsakonas said. "In order to know how the proteins work you must know who they talk to. And then you can examine whether a disease somehow alters this conversation."

A pivotal part of this research involved a scientific technique called mass spectrometry, which is relatively new to the science of biology. The ultra-precise mass spectrometry experiments were done by HMS professor of cell biology Steven Gygi. Mass spectrometry is used to measure the exact weight (the mass) and thus identify each individual protein in a sample. It is a technique originally devised by physicists for analyzing atomic particles. But in recent years mass spectrometry was adapted and refined for new and powerful uses in basic biological research. Other studies using similar techniques to date have focused on small groups of related proteins or single celled model organisms such as bacteria and yeast.

Despite the huge amount already known about the fruit fly and its genetic endowment, much about the function of thousands of proteins remains a mystery. This map, however, now gives us precise clues about their function. Filling in the detailed protein map can help scientists gain important insights into the process of development, that is, how a creature is put together, maintained and operated.

"Our analyses also sheds light on how proteins and protein networks have evolved in different animals," said K. G. Guruharsha, a postdoctoral fellow in Artavanis-Tsakonas's lab and a first author on the paper.

Co-lead authors on the paper included Jean-Francois Rual, also a postdoctoral fellow in Artavanis-Tsakonas's lab, and Julian Mintseris and Bo Zhai, both research fellows in Gygi's lab.

Also important in this effort was the work of K. VijayRaghavan, at the National Centre for Biological Sciences in Bangalore, India. Similarly, crucial contributions to this work also came from the University of California, in Berkeley, where Susan E. Celniker collaborated through her studies in the fruit fly genome center.

This research was funded by the National Institutes of Health.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Harvard Medical School. The original article was written by Robert Cooke.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

ScienceDaily (Oct. 27, 2011) — Robert Linhardt is working to forever change the way some of the most widely used drugs in the world are manufactured. In a new studying appearing in the journal Science, he and his partner in the research, Jian Liu, have announced an important step toward making this a reality.

Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Biocatalysis and Metabolic Engineering at Rensselaer Polytechnic Institute, and Jian Liu, a professor in the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, have discovered an entirely new process to manufacture ultra-low molecular weight heparin.

The research shows that the drug is identical in performance and safety to the current and successful anticoagulant fondaparinux, but is purer, faster, and less expensive to produce.

"This research represents an entirely new paradigm in drug manufacturing," Linhardt said. "With this discovery, we have successfully demonstrated that replacing the current model of drug production with a chemoenzymatic approach can greatly reduce the cost of drug development and manufacturing, while also increasing drug performance and safety, and reduce the possibility of outside drug contamination. It is our hope that this is the first step in the adoption of this method for the manufacture of many other drugs."

The new process uses chemicals and enzymes to reduce the number of steps in production of fondaparinux from approximately 50 steps down to just 10 to 12. In addition, it increases the yield from that process 500-fold compared to the current fondaparinux process, and could decrease the cost of manufacture by a similar amount, according to Linhardt.

Fondaparinux, which is sold as a name-brand drug and was also recently approved by the FDA as a generic drug, is a synthetic anticoagulant used to treat deep vein thrombosis, with over $500 million in annual sales. It is part of a much larger family of anticoagulant drugs known as heparins. But, unlike most heparin products, it is chemically synthesized from non-animal materials. All other heparin-based drugs currently on the market use materials from the intestines of pigs and lungs of cattle as source materials. Such animal materials are more likely to become contaminated, according to Linhardt.

"When we rely on animals, we open ourselves up for spreading viruses and prion diseases like mad cow disease through the use of these heparins," Linhardt said. "And because most of the raw material is imported, we often can't be sure of exactly what we are getting."

But, fondaparinux is extremely costly to produce, according to Linhardt. "The process to produce the drug involves many steps to purify the material and creates tons and tons of hazardous waste to dispose of," Linhardt said.

The new process developed by Linhardt and Liu greatly reduces the number of steps involved in the production of the drug. This reduces the amount of waste produced and the overall cost of producing the drug.

"Cost should no longer be a major factor in the use or production of this drug," Linhardt said.

The process uses sugars and enzymes that are identical to those found in the human body to build the drug piece by piece. The backbone of the material is first built sugar by sugar and then decorated with sulfate groups through the use of enzymes to control its structure and function in the body.

Linhardt and Liu have already begun testing the drug in animal models with successful results and think the drug could be quickly transferred to the market.

"Because the new drug is biologically identical in its performance to the already approved fondaparinux, the approval process for this new drug should work very similar to the approval process used for fondaparinux," Linhardt said. He also thinks that this combined chemical and enzymatic synthesis can be quickly brought to patients in need and adapted for the production of many other improved carbohydrate-containing drugs.

"During this study, we were able to quickly build multiple doses in a simple laboratory setting and feel that this is something than can be quickly and easy commercialized to reduce the cost of this drug and help to shift how pharmaceutical companies approach the synthesis of carbohydrate-containing drugs."

The finding is part of a much larger body of work occurring in the Linhardt lab to completely replace all types of heparin-based or other glycoprotein-based drugs with safer, low-cost, synthetic versions that do not rely on foreign, potentially contaminated animal sources.

The research is funded by the National Institutes of Health.

Linhardt and Liu were joined in the research by Yongmei Xu, Haoming Xu, Renpeng Liu, and Juliana Jing of the University of North Carolina, Chapel Hill; Sayaka Masuko of Rensselaer Polytechnic Institute; and Majde Takieddin and Shaker Mousa of the Albany College of Pharmacy and Health Sciences.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Rensselaer Polytechnic Institute.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Yongmei Xu, Sayaka Masuko, Majde Takieddin, Haoming Xu, Renpeng Liu, Juliana Jing, Shaker A. Mousa, Robert J. Linhardt, Jian Liu. Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins. Science, 2011; 334 (6055): 498-501 DOI: 10.1126/science.1207478

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

If you want to enjoy Forex trading success, then this article will put you on the road to building wealth in just 30 minutes a day. Anyone can become a successful Forex trader, so let’s look at how to do it.

The first point you need to keep in mind is that while anyone can learn to trade, you do have to make an effort to learn skills and work. Most new traders however buy a cheap, junk piece of software and think there going to get rich with no effort!

Of course, they all lose, of Forex trading was that easy, 95% of traders wouldn’t lose money.

So if you want to win you need to make an effort and get a good Forex education but the good news is you can get a simple Forex trading strategy together which you can make big gains with in around 2 weeks or even less.

While many people think complicated strategies are best, the opposite is actually true, simple systems work better because they are more robust.

Don’t make Forex trading harder or more complicated than it needs to be, you don’t get rewarded for effort by the markets just results – so don’t spend endless hours, trying to find the holy grail system when there isn’t one.

Anyone can learn a method that can make money, this is the easy part of becoming a Forex trader; the harder part is trading your system with discipline through losses.

A lack of discipline causes more accounts to be wiped out, than any other reason – so why is it so hard?

No one likes to be wrong and look a fool but the Forex market will do this to you often and when you start to lose, your emotions come into play, as they do with any trader and you must control them.

If you get angry, start to trade to much, run losses or start swapping systems, you are going to lose.

In times of losses, you just need to keep them small, until you hit profits again. Sounds simple but very few traders can do it but if you can learn, a simple method and execute your system with discipline, you can make a lot of money in 30 minutes a day or less.

So if you want to be a successful trader you can, just be prepared to get the right education and adopt a disciplined mindset and Forex success can be yours.

NEW! 2 X FREE ESSENTIAL TRADER PDFS
ESSENTIAL FOREX TRADING COURSE

For free 2 x trading Pdf’s, with 50 of pages of essential Forex info and the best PROVEN Forex trading Techniques visit our website at: http://www.learncurrencytradingonline.com.
If you want to enjoy Forex trading success, then this article will put you on the road to building wealth in just 30 minutes a day. Anyone can become a successful Forex trader, so let’s look at how to do it.

The first point you need to keep in mind is that while anyone can learn to trade, you do have to make an effort to learn skills and work. Most new traders however buy a cheap, junk piece of software and think there going to get rich with no effort!

Of course, they all lose, of Forex trading was that easy, 95% of traders wouldn’t lose money.

So if you want to win you need to make an effort and get a good Forex education but the good news is you can get a simple Forex trading strategy together which you can make big gains with in around 2 weeks or even less.

While many people think complicated strategies are best, the opposite is actually true, simple systems work better because they are more robust.

Don’t make Forex trading harder or more complicated than it needs to be, you don’t get rewarded for effort by the markets just results – so don’t spend endless hours, trying to find the holy grail system when there isn’t one.

Anyone can learn a method that can make money, this is the easy part of becoming a Forex trader; the harder part is trading your system with discipline through losses.

A lack of discipline causes more accounts to be wiped out, than any other reason – so why is it so hard?

No one likes to be wrong and look a fool but the Forex market will do this to you often and when you start to lose, your emotions come into play, as they do with any trader and you must control them.

If you get angry, start to trade to much, run losses or start swapping systems, you are going to lose.

In times of losses, you just need to keep them small, until you hit profits again. Sounds simple but very few traders can do it but if you can learn, a simple method and execute your system with discipline, you can make a lot of money in 30 minutes a day or less.

So if you want to be a successful trader you can, just be prepared to get the right education and adopt a disciplined mindset and Forex success can be yours.

NEW! 2 X FREE ESSENTIAL TRADER PDFS
ESSENTIAL FOREX TRADING COURSE

For free 2 x trading Pdf’s, with 50 of pages of essential Forex info and the best PROVEN Forex trading Techniques visit our website at: http://www.learncurrencytradingonline.com.